Abstract Library

#2887 CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study

Introduction: Comparative data suggest greater accuracy of Choi vs RECIST in some cancers such as pancreatic neuroendocrine tumors (panNET) treated with antiangiogenic agents.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Jimenez-Fonseca P, Fernandez del Valle A, Solis M, Garcia Carbonero R, Custodio A,

Keywords: CHOI, RECIST, Response, Sunitinib, Survival,

#2058 On-going Evaluation of the Use of Resources and the Costs (UR/C) Associated with Controlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine Tumours (NETs): RECOSY Study Design

Introduction: NET pts have high rates of mortality and morbidity, as wells as decreased health-related quality of life (HRQoL) due to CS. Though there is little research on the economic impact of CS, recent studies show that some symptoms, i.e. diarrhoea, are associated with higher healthcare expenditure and use of resources.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Custodio A, Carmona-Bayonas A, Villabona C, Perez M, de La Cruz G,

Keywords: neuroendocrine tumors, carcinoid syndrome, use of resources, costs,

#1937 Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study

Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Solis-Hernandez M

Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,

Keywords: Sunitinib, targeted therapies,

#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,

Keywords: sunitinib, PNET, choi, recist,

#1926 Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)

Introduction: RGETNE is a national hospital-based GEP-NENs registry coordinated by the Spanish multidisciplinary scientific society GETNE.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jimenez-Fonseca P, Castaño A, Pi Barrio J, Alonso V, Custodio A,

Keywords: Multivariate, neuroendocrine tumor, prognostic factors, registry, survival, univariate,